MoonLake Immunotherapeutics
MLTX
Positions held
Your positionsMLTX isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- MoonLake Immunotherapeutics operates in the promising biotechnology sector, focusing on innovative therapies that address unmet medical needs, which can attract significant investor interest.
- The company's current ratio stands at 12.558, indicating a strong liquidity position to cover short-term liabilities.
- Despite recent losses, the target mean price for MLTX is $28.54, suggesting a potential upside from its current valuation.
- The biotechnology industry is highly competitive, and MoonLake Immunotherapeutics faces challenges in achieving profitability with a profit margin of 0.0%.
- In the last four quarters, the company reported net income losses ranging from -61.805 million to -69.729 million, reflecting ongoing financial struggles.
- The stock has a 'Sell' signal with a score of -6.00, indicating negative market sentiment and potential downward pressure on its price.
Fundamentals
| Market cap | $900.43M | Enterprise value | $464.93M | Trailing P/E | — | Forward P/E | -3.18 |
| PEG | — | Price / book | 2.07 | Beta | 1.08 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -67.5% | ROA | -32.4% | Debt / equity | 0.24 |
| Current ratio | 12.56 | Free cash flow | -$131.86M | Analyst recommendation | buy | Mean target | $28.54 |
| 52w high | $23.29 | 52w low | $8.80 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$61.8M | -$69.7M | -$62.4M | -$69.7M | -$55.2M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$61.7M | -$70.0M | -$65.2M | -$71.4M | -$60.7M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — |
| Net income | -$227M | -$119M | -$36.0M | -$50.0M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$245M | -$143M | -$54.1M | -$65.1M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-05 · MoonLake Immunotherapeutics Could Win FDA Approval for Sonelokimab by Year-End 2027, Wedbush Says
2026-09-21 · Psoriatic Arthritis Market Landscape: 6 Key Late-Stage Drugs Set to Drive Future Growth | DelveInsight
2026-09-11 · MLTX Stock On Track For Worst Week Since Last Fall As FDA Filing Date For Skin Disease Drug Draws Near
2026-08-10 · MoonLake Immunotherapeutics Q2 Loss Narrows, Phase 3 PsA Trial Meets Clinical Goals
2026-08-03 · MLTX Stock Under Pressure As Investors Await Psoriatic Arthritis Trial Data
2026-07-31 · Wall Street Analysts See a 73.35% Upside in MOONLAKE IMMUNO (MLTX): Can the Stock Really Move This High?
2026-07-31 · Wall Street Analysts See a 73.35% Upside in MOONLAKE IMMUNO (MLTX): Can the Stock Really Move This High?
2026-07-20 · Moonlake Immunotherapeutics Insider Sold Shares Worth $322,261, According to a Recent SEC Filing
2026-07-13 · SLS Vs MLTX: Retail Traders Race To Pick Merck’s Next Biotech Buyout As Keytruda’s $31.7B Patent Cliff Nears
Price (daily)
Full chart · RSI · MACD · patterns